There’s a particular flavor of biotech origin story I love — the one where a senior exec at a well-funded platform company looks at the asset shelf, sees something nobody’s prioritizing, and says I’ll take that, thanks. That’s basically Tenvie Therapeutics in a nutshell. Founded in January 2025 by Tony Estrada, PhD — formerly SVP and Head of Discovery Sciences at Denali Therapeutics — the company scooped up a portfolio of small molecule programs and immediately raised a $200 million Series A led by ARCH Venture Partners and F-Prime Capital. Not a bad opening hand.

Now, barely 15 months later, Tenvie has dosed its first patient in a Phase 1a/1b trial of TNV262, a fully CNS-penetrant small molecule NLRP3 inhibitor. The trial is enrolling healthy volunteers and people with obesity across single- and multiple-ascending dose cohorts, with cardiovascular and inflammatory biomarker endpoints baked in. Preliminary data expected in the second half of 2026.

Here’s what makes this interesting. The NLRP3 inflammasome space is getting crowded — but almost everyone else is pointing their inhibitors at neurodegeneration or ophthalmology.

Tenvie is the only one explicitly going after obesity and cardiovascular disease with a brain-penetrant NLRP3 approach. The thesis: hypothalamic inflammation is a key driver of metabolic dysfunction, and if you can cross the blood-brain barrier to shut down NLRP3 in the brain, you might unlock durable weight loss through a completely different mechanism than GLP-1s. Their preclinical data showed reversal of hypothalamic inflammation and sustained weight loss in diet-induced obesity models.

The broader Tenvie pipeline includes a SARM1 inhibitor for peripheral neuropathies and programs targeting TRPML1 and TMEM175 — all built on their platform’s ability to engineer molecules that are either highly CNS-penetrant or peripherally restricted. It’s a clever design principle that gives them optionality across neuro, cardio, and metabolic indications.

With $200M in the bank and a Denali pedigree backing the science, this is one to watch. The Phase 1 data later this year will tell us whether TNV262’s CNS penetration translates into the kind of biomarker signal that gets cardiometabolic investors very, very excited.